Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor. The fully implantable device is replaced once a year, lasting 185 days longer than the Eversense E3 sensor and outstripping competing CGMs, which last only for 10-14 days.

• Source: Shutterstock (Shutterstock)

More from Business

More from Medtech Insight